» Articles » PMID: 26901358

Risk of Nosocomial Respiratory Syncytial Virus Infection and Effectiveness of Control Measures to Prevent Transmission Events: a Systematic Review

Overview
Publisher Wiley
Specialty Microbiology
Date 2016 Feb 23
PMID 26901358
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Respiratory syncytial virus (RSV) causes a significant public health burden, and outbreaks among vulnerable patients in hospital settings are of particular concern. We reviewed published and unpublished literature from hospital settings to assess: (i) nosocomial RSV transmission risk (attack rate) during outbreaks, (ii) effectiveness of infection control measures. We searched the following databases: MEDLINE, EMBASE, CINAHL, Cochrane Library, together with key websites, journals and grey literature, to end of 2012. Risk of bias was assessed using the Cochrane risk of bias tool or Newcastle-Ottawa scale. A narrative synthesis was conducted. Forty studies were included (19 addressing research question one, 21 addressing question two). RSV transmission risk varied by hospital setting; 6-56% (median: 28·5%) in neonatal/paediatric settings (n = 14), 6-12% (median: 7%) in adult haematology and transplant units (n = 3), and 30-32% in other adult settings (n = 2). For question two, most studies (n = 13) employed multi-component interventions (e.g. cohort nursing, personal protective equipment (PPE), isolation), and these were largely reported to be effective in reducing nosocomial transmission. Four studies examined staff PPE; eye protection appeared more effective than gowns and masks. One study reported on RSV prophylaxis for patients (RSV-Ig/palivizumab); there was no statistical evidence of effectiveness although the sample size was small. Overall, risk of bias for included studies tended to be high. We conclude that RSV transmission risk varies widely during hospital outbreaks. Although multi-component control strategies appear broadly successful, further research is required to disaggregate the effectiveness of individual components including the potential role of palivizumab prophylaxis.

Citing Articles

Risk of nosocomial respiratory syncytial virus versus influenza among adult patients in acute care hospitals.

Auvinen R, Huotari K, Nohynek H, Syrjanen R, Skogberg K Infect Prev Pract. 2025; 7(1):100431.

PMID: 39896063 PMC: 11782808. DOI: 10.1016/j.infpip.2024.100431.


Clinical Outcomes and Characteristics of COVID-19 in Neonates: A Single-Center Study in Romania.

Cocuz M, Cocuz I, Rodina L, Filip R, Filip F Life (Basel). 2025; 14(12.

PMID: 39768357 PMC: 11677269. DOI: 10.3390/life14121650.


Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece.

Gourzoulidis G, Tzanetakos C, Solakidi A, Markatis E, Detsis M, Mendes D Vaccines (Basel). 2024; 12(11).

PMID: 39591135 PMC: 11598676. DOI: 10.3390/vaccines12111232.


Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel.

Michelin L, Bellei N, Ferreira da Costa Gomes M, Raboni S, Kairalla M, Correa R Hum Vaccin Immunother. 2024; 20(1):2388943.

PMID: 39161095 PMC: 11340750. DOI: 10.1080/21645515.2024.2388943.


Respiratory Syncytial Virus (RSV) Hospitalizations in the Elderly in a Tertiary Care Hospital in Southern Italy as a Useful Proxy for Targeting Vaccine Preventive Strategies.

Centrone F, Loconsole D, Marziani A, Orlando V, Delle Fontane A, Minelli M Infect Dis Rep. 2024; 16(3):491-498.

PMID: 38920893 PMC: 11204164. DOI: 10.3390/idr16030037.


References
1.
Gardner P, Court S, Brocklebank J, Downham M, Weightman D . Virus cross-infection in paediatric wards. Br Med J. 1973; 2(5866):571-5. PMC: 1592186. DOI: 10.1136/bmj.2.5866.571. View

2.
Alan S, Okulu E, Kilic A, Atasay B, Arsan S . Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit. J Hosp Infect. 2012; 81(4):292-3. PMC: 7134468. DOI: 10.1016/j.jhin.2012.05.011. View

3.
Visser A, Delport S, Venter M . Molecular epidemiological analysis of a nosocomial outbreak of respiratory syncytial virus associated pneumonia in a kangaroo mother care unit in South Africa. J Med Virol. 2008; 80(4):724-32. DOI: 10.1002/jmv.21128. View

4.
Raad I, Abbas J, Whimbey E . Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med. 1997; 102(3A):48-52; discussion 53-4. DOI: 10.1016/s0002-9343(97)00011-9. View

5.
Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P . Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis. 2014; 14:665. PMC: 4269936. DOI: 10.1186/s12879-014-0665-2. View